Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine + capecitabine as first-line treatment in advanced breast cancer with non-measurable lesions
2005-005680-29Phase 2Active
- Sponsor
- San Luigi Gonzaga Hospital
- Start
- Feb 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and capecitabine in breast cancer, sponsored by San Luigi Gonzaga Hospital. Primary endpoint: Time to progression. Started Feb 2007; status: active.
02
Drugs
vinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005680-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005680-29.